secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2025-06-18T23:59:59+00:00
Accession:  0001213900-25-055700
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals closes $3.6M public offering of common stock and warrants; amends existing warrants
--------------------------------------------------------------------------------

- Gross proceeds of ~$3.6M from sale of 11.1M shares (or equivalents) plus Series D and E warrants at $0.3251/unit.
- Series D warrants exercisable at $0.35, expire 5 years after stockholder approval; Series E warrants expire 18 months post-approval.
- Existing Series B-1 and C-1 warrants amended: exercise price cut from $0.74 to $0.35, expiration extended to 2030 and 2026 respectively.
- Offering closed June 18, 2025; net proceeds to be used for working capital and general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025055700/0001213900-25-055700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025055700/ea0246131-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-055700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer